

# Author Index for Volume 14

- Amato DA, 523  
Anderson GL, 308  
Anderson MM, Jr, 123  
Anthonisen NR, 68S  
Appel LJ, 569  
Armstrong JA, 523  
Ashish S, 467
- Backlund J-Y, 123  
Bailey WC, 3S  
Balmes J, 308  
Barnhart S, 308  
Bartlett JG, 6, 523  
Beck RW, 123, 143  
Berendes HW, 179  
Berge KG, 350  
Bjornson-Benson WM, 38S, 52S  
Boissel J-P, 344  
Braga M, 296  
Brooks HB, 500  
Brown BW, Jr, 109  
Buchwald H, 500  
Buist AS, 20S, 52S
- Cherniack M, 308  
Clark CM, Jr, 30  
Cleary PA, 123, 143  
Coe PR, 19  
Cole BF, 485  
Collaborative Ocular Melanoma Study Group, 362  
Collins D, 6  
Cone J, 308  
Connett JE, 3S, 20S, 38S  
Corle DK, 253  
Counts GW, 523  
Coyne T, 538  
Cullen MR, 308
- Dafni U, 523  
Daniels K, 38S  
Davis BR, 350  
de Velasco A, 538  
DeMets D, 6  
DeMets DL, 183  
Deykin D, 6  
Drabik MJ, 538  
Dumont J-M, 209  
Durkin DA, 20S
- Edelstein C, 325
- Feorino P, 6  
Finlay RA, 538  
Fitch LL, 500  
Fleming TR, 183
- Gail M, 6  
Gail MH, 253  
Gassman JJ, 538  
Gelber RD, 485  
George SL, 511  
Gilbert PR, 123  
Gladstone P, 45  
Glass A, 308  
Godfrey E, 523  
Goldhirsch A, 485  
Goodman GE, 308  
Grizzle JE, 308
- Halpern J, 109  
Hamilton JD, 6  
Hammer S, 308  
Hansen BJ, 500  
Hartigan PM, 6  
Hawkins CM, 350  
Higginson L, 45  
Hillis A, 560  
Hughes JR, 176
- International Breast Cancer Study Group, 485
- Jobe AH, 75  
Johnson CA, 143  
Johnson JW, 500
- Keltner JL, 143  
Kenny DJ, 123  
Keogh JP, 308  
Kiefer S, 538  
Kimball B, 45  
Kjelsberg MO, 20S  
Korn EL, 286  
Kusek JW, 3S, 538
- Lachin JM, 471  
Lakatos E, 350  
Lange N, 247  
Langenberg P, 467  
Lee YJ, 179
- Leedom JM, 523  
Leite MLC, 296  
LeMay M, 45  
Lespérance J, 45  
Louis TA, 252  
Lund B, 325  
Lung Health Study Research Group, 1S, 3S, 20S, 38S  
Lunghofer B, 523
- Manfreda J, 68S  
Manske KA, 52S  
Mark SD, 79  
Marubini E, 296  
Matts JP, 500  
McKellar J, 568  
McMahon RP, 244  
Meinert CL, 255  
Meyskens F, Jr, 308  
Miller LL, 286  
Moyé LA, 249, 350
- ODES Investigators, 229  
O'Hara P, 3S  
Omenn GS, 308, 32S  
Optic Neuritis Study Group, 123, 143  
Owens GR, 20S
- Peterson B, 511  
Petroccione A, 296  
Pettit P, 261  
Piantadosi S, 562  
Pirotta N, 296  
PMA Biostatistics and Medical Ad Hoc Committee on Interim Analysis, 160  
POSCH Group, 500  
Powers SN, 538  
Pressel S, 350  
Pritchett W, 6  
Probstfield JL, 350
- Recruitment Directors of the Lung Health Study for the Lung Health Study Research Group, 20S

Redfield R, 6  
 Roberts R, 6  
 Robins JM, 79  
 Rosenberger WF, 471  
 Rosendorf LL, 523  
 Rosenstock L, 308  
 Rudick C, 68S

Senn S, 1  
 Shuster JJ, 198  
 Siebert C, 30  
 Silverman WA, 347  
 Simberkoff MS, 6  
 SINBA Group, 296  
 Spaeth GL, 174, 340

Spritz N, 6  
 Spurr JO, 143  
 Steinman TI, 538  
 Stibolt TB, 52S  
 Stuenkel MR, 500  
 Sukkestad E, 523

Tamhane AC, 19  
 Therneau TM, 98  
 Thornquist MD, 308, 325  
 Tonse NK, 467  
 Tseng A, 325  
 Tukey JW, 266

Urban N, 325

VA Cooperative Study  
 Group on AIDS  
 Treatment, 6  
 Valanis B, 308

Wara DW, 523  
 Waters D, 45  
 Wenzel RP, 6  
 Williams JH, Jr, 308  
 Wittes J, 350, 562  
 Wu M, 3S

Youtsey DJ, 52S  
 Yu KF, 286

Zavela KJ, 52S

---

# Subject Index for Volume 14

---

## **ACCELERATED FAILURE TIME MODEL**

A Method for the Analysis of Randomized Trials with Compliance Information: An Application to the Multiple Risk Factor Intervention Trial, 79

## **ACCIDENTAL BIAS**

How Many Stratification Factors Are "Too Many" to Use in a Randomization Plan?, 98

## **ACTIVE CONTROL TRIALS**

Monitoring of Clinical Trials: Issues and Recommendations, 183

## **ADAPTIVE ALLOCATION**

How Many Stratification Factors Are "Too Many" to Use in a Randomization Plan?, 98

## **ADHERENCE**

Research Cost Analyses to Aid in Decision Making in the Conduct of a Large Prevention Trial, CARET, 325

## **ADJUSTMENT FOR COVARIATES**

Tightening the Clinical Trial, 266

## **ADMINISTRATIVE ANALYSES**

Monitoring of Clinical Trials: Issues and Recommendations, 183

## **AIDS**

Performance Evaluation in Multicenter Clinical Trials: Development of a Model by the AIDS Clinical Trial Group, 523

## **ALTHAM'S MODEL**

"Within Patient"-Dependent Outcomes in Graft Occlusion After Coronary Artery Bypass, 296

## **AUTOMATED PERIMETRY**

Quality Control Functions of the Visual Field Reading Center (VFRC) for the Optic Neuritis Treatment Trial (ONTT), 143

## **BAYESIAN ANALYSIS**

Stopping a Clinical Trial Very Early Because of Toxicity: Summarizing the Evidence, 286

## **BEHAVIORAL INTERVENTION**

Design of the Lung Health Study: A Randomized Clinical Trial of Early Intervention for Chronic Obstructive Pulmonary Disease, 35

## **BERKSON'S SIMPLE DIFFERENCE**

Exact Repeated Confidence Intervals for Bernoulli Parameters in a Group Sequential Clinical Trial, 19

## **BINOMIAL DISTRIBUTION**

Exact Repeated Confidence Intervals for Bernoulli Parameters in a Group Sequential Clinical Trial, 19  
Fixing the Number of Events in Large Comparative Trials With Low Event Rates: A Binomial Approach, 198

## **$\beta$ -BINOMIAL MODEL**

"Within Patient"-Dependent Outcomes in Graft Occlusion After Coronary Artery Bypass, 296

## **BLOOD PRESSURE MEASUREMENT**

Note on the Value of 24-Hour Ambulatory Blood Pressure Devices (letter), 568

## **BOOK REVIEW**

Medical Statistics: A Commonsense Approach, by Campbell MJ and Machin D, 251

## **CENSORED SURVIVAL DATA**

Fixing the Number of Events in Large Comparative Trials With Low Event Rates: A Binomial Approach, 198

## **CENTRAL LABORATORY**

In Response to an Article by Lemuel Moyé (CCT 12(6)) Entitled "Central Laboratory Sampling Plans and Quality Control in Clinical Trials" (letters), 244, 247

**CHEMOPREVENTION**

- Research Cost Analyses to Aid in Decision Making in the Conduct of a Large Prevention Trial, CARET, 325  
Statistical Design and Monitoring of the Carotene and Retinol Efficacy Trial (CARET), 308

**CHOLESTEROL REDUCTION**

- Effect of Cholesterol Reduction by Simvastatin on Progression of Coronary Atherosclerosis: Design, Baseline Characteristics, and Progress of the Multicenter Anti-Atheroma Study (MAAS), 209

**CHOROIDAL MELANOMA**

- Design and Methods of a Clinical Trial for a Rare Condition: The Collaborative Ocular Melanoma Study, 362

**CHRONIC OBSTRUCTIVE PULMONARY DISEASE**

- Recruiting Healthy Participants for a Large Clinical Trial, 68S  
Recruitment of Participants in the Lung Health Study, I: Description of Methods, 20S

**CLINICAL TRIAL DESIGN**

- How Many Stratification Factors Are "Too Many" to Use in a Randomization Plan?, 98

**CLINICAL TRIALS**

- A Computer Program for Designing Clinical Trials with Arbitrary Survival Curves and Group Sequential Testing, 109  
Design of the Lung Health Study: A Randomized Clinical Trial of Early Intervention for Chronic Obstructive Pulmonary Disease, 3S  
Ethical Dilemmas in Continuing a Zidovudine Trial After Early Termination of Similar Trials, 6  
Exclusion of "Noncompliant" Individuals from Clinical Trials (letter), 176  
Letters, 340, 344  
Monitoring Recruitment Effectiveness and Cost in a Clinical Trial, 52S  
The Oslo Diet and Exercise Study (ODES): Design and Objectives, 229  
Politically Correct Clinical Trials (letter), 562  
Quality Control Functions of the Visual Field Reading Center (VFRC) for the

- Optic Neuritis Treatment Trial (ONTT), 143

- Recruiting Healthy Participants for a Large Clinical Trial, 68S  
Recruitment of Participants in the Lung Health Study, I: Description of Methods, 20S  
Recruitment of Participants in the Lung Health Study, II: Assessment of Recruiting Strategies, 38S  
Resolution on Clinical Trials (letter), 560  
Treatment Effect Size in Clinical Trials: An Example from Surfactant Trials, 467

**COMPLIANCE**

- A Method for the Analysis of Randomized Trials with Compliance Information: An Application to the Multiple Risk Factor Intervention Trial, 79

**COMPUTER PROGRAM**

- A Computer Program for Designing Clinical Trials with Arbitrary Survival Curves and Group Sequential Testing, 109

**CONDITIONAL POWER**

- Statistical Considerations in Monitoring the Systolic Hypertension in the Elderly Program (SHEP), 350

**CONFIDENCE INTERVAL**

- Stopping a Clinical Trial Very Early Because of Toxicity: Summarizing the Evidence, 286

**CONTROLLED CLINICAL TRIAL**

- Design, Methods, and Conduct of the Optic Neuritis Treatment Trial, 123

**CORONARY ATHEROSCLEROSIS**

- Design Features of a Controlled Clinical Trial to Assess the Effect of an HMG CoA Reductase Inhibitor on the Progression of Coronary Artery Disease, 45  
Effect of Cholesterol Reduction by Simvastatin on Progression of Coronary Atherosclerosis: Design, Baseline Characteristics, and Progress of the Multicenter Anti-Atheroma Study (MAAS), 209

**CORPORATE AUTHORSHIP**

- In Defense of the Corporate Author for Multicenter Trials, 255



**COST(S)**

- Monitoring Recruitment Effectiveness and Cost in a Clinical Trial, 52S
- Resolution on Clinical Trials (letter), 560

**COST EFFECTIVENESS**

- Research Cost Analyses to Aid in Decision Making in the Conduct of a Large Prevention Trial, CARET, 325

**DATA MONITORING**

- Response to McMahon and Lange (letter), 249
- Statistical Considerations in Monitoring the Systolic Hypertension in the Elderly Program (SHEP), 350

**DATA-MONITORING COMMITTEES**

- Monitoring of Clinical Trials: Issues and Recommendations, 183

**DEATH**

- From "Tame" to "Forbidden" Death, 347

**DEPENDENT OUTCOMES**

- "Within Patient"-Dependent Outcomes in Graft Occlusion After Coronary Artery Bypass, 296

**DESIGN**

- Design and Methods of a Clinical Trial for a Rare Condition: The Collaborative Ocular Melanoma Study, 362

**DIETARY TREATMENT**

- The Oslo Diet and Exercise Study (ODES): Design and Objectives, 229

**DIETHYLSTILBESTROL**

- The 1953 Clinical Trial of Diethylstilbestrol During Pregnancy: Could It Have Stopped DES Use?, 179

**DOCUMENTATION**

- Operational and Policy Considerations of Data Monitoring in Clinical Trials: The Diabetes Control and Complications Trial Experience, 30

**DOUBLE RANDOMIZATION**

- Tightening the Clinical Trial, 266

**EARLY STOPPING**

- Ethical Dilemmas in Continuing a Zidovudine Trial After Early Termination of Similar Trials, 6

- Stopping a Clinical Trial Very Early Because of Toxicity: Summarizing the Evidence, 286

**ENUCLEATION**

- Design and Methods of a Clinical Trial for a Rare Condition: The Collaborative Ocular Melanoma Study, 362

**ERRATUM, 253****ETHICS**

- Ethical Dilemmas in Continuing a Zidovudine Trial After Early Termination of Similar Trials, 6
- Instituting a Research Ethic, 261
- The Use of Response-Adaptive Designs in Clinical Trials, 471

**FACTORIAL DESIGN**

- Sample Size Requirements and Length of Study for Testing Interaction in a  $1 \times k$  Factorial Design when Time-to-Failure Is the Outcome, 511

**FIBRINOLYSIS**

- The Oslo Diet and Exercise Study (ODES): Design and Objectives, 229

**FISHER'S EXACT TEST**

- Fixing the Number of Events in Large Comparative Trials With Low Event Rates: A Binomial Approach, 198

- Stopping a Clinical Trial Very Early Because of Toxicity: Summarizing the Evidence, 286

**GLUCOSE METABOLISM**

- The Oslo Diet and Exercise Study (ODES): Design and Objectives, 229

**GRAFT PATENCY**

- "Within Patient"-Dependent Outcomes in Graft Occlusion After Coronary Artery Bypass, 296

**GROUP SEQUENTIAL DESIGN**

- A Computer Program for Designing Clinical Trials with Arbitrary Survival Curves and Group Sequential Testing, 109
- Monitoring of Clinical Trials: Issues and Recommendations, 183
- Stopping a Clinical Trial Very Early Because of Toxicity: Summarizing the Evidence, 286

**GROUP SEQUENTIAL METHODS**

Fixing the Number of Events in Large Comparative Trials With Low Event Rates: A Binomial Approach, 198

**HEMOSTASIS**

The Oslo Diet and Exercise Study (ODES): Design and Objectives, 229

**HIV INFECTION**

Ethical Dilemmas in Continuing a Zidovudine Trial After Early Termination of Similar Trials, 6

**HMG-CoA REDUCTASE INHIBITORS**

Design Features of a Controlled Clinical Trial to Assess the Effect of an HMG CoA Reductase Inhibitor on the Progression of Coronary Artery Disease, 45

Effect of Cholesterol Reduction by Simvastatin on Progression of Coronary Atherosclerosis: Design, Baseline Characteristics, and Progress of the Multicenter Anti-Atheroma Study (MAAS), 209

**HYPERLIPIDEMIAS**

Perception of Quality of Life Before and After Disclosure of Trial Results: A Report from the Program on the Surgical Control of Hyperlipidemias (POSCH), 500

**ILIAL BYPASS**

Perception of Quality of Life Before and After Disclosure of Trial Results: A Report from the Program on the Surgical Control of Hyperlipidemias (POSCH), 500

**INFORMED CONSENT**

Ethical Dilemmas in Continuing a Zidovudine Trial After Early Termination of Similar Trials, 6

**INHALED BRONCHODILATOR**

Design of the Lung Health Study: A Randomized Clinical Trial of Early Intervention for Chronic Obstructive Pulmonary Disease, 35

**INTERIM ANALYSIS**

A Computer Program for Designing Clinical Trials with Arbitrary Survival Curves and Group Sequential Testing, 109  
Exact Repeated Confidence Intervals for

Bernoulli Parameters in a Group Sequential Clinical Trial, 19

Interim Analysis in the Pharmaceutical Industry, 160

Monitoring of Clinical Trials: Issues and Recommendations, 183

**KINETIC PERIMETRY**

Quality Control Functions of the Visual Field Reading Center (VFRC) for the Optic Neuritis Treatment Trial (ONTT), 143

**LAG TIME**

Statistical Considerations in Monitoring the Systolic Hypertension in the Elderly Program (SHEP), 350

**LESS-THAN-PERFECT ADJUSTMENT**

Tightening the Clinical Trial, 266

**LETTERS TO THE EDITOR, 340, 344**

Concerning Silverman's Suspended Judgment Article "The Most Noble Goal Of Medicine" Published December 1991, 174

Exclusion of "Noncompliant" Individuals from Clinical Trials, 176

In Response to an Article by Lemuel Moyé (CCT 12(6)) Entitled "Central Laboratory Sampling Plans and Quality Control in Clinical Trials," 244, 247

Note on the Value of 24-Hour Ambulatory Blood Pressure Devices, 568

Politically Correct Clinical Trials, 562

Resolution on Clinical Trials, 560

Response to McMahon and Lange, 249

**LIPIDS AND LIPOPROTEINS**

The Oslo Diet and Exercise Study (ODES): Design and Objectives, 229

**LOG-RANK TEST**

A Method for the Analysis of Randomized Trials with Compliance Information: An Application to the Multiple Risk Factor Intervention Trial, 79

**LUNG CANCER**

Statistical Design and Monitoring of the Carotene and Retinol Efficacy Trial (CARET), 308

**LUNG DISEASE**

Monitoring Recruitment Effectiveness and Cost in a Clinical Trial, 525

**LUNG HEALTH STUDY**

- APPENDIX, Lung Health Study  
Participants, 80S  
Design of the Lung Health Study: A  
Randomized Clinical Trial of Early  
Intervention for Chronic  
Obstructive Pulmonary Disease, 3S  
The Lung Health Study: Introduction, 1S  
Monitoring Recruitment Effectiveness and  
Cost in a Clinical Trial, 52S  
Recruiting Healthy Participants for a  
Large Clinical Trial, 68S  
Recruitment of Participants in the Lung  
Health Study, I: Description of  
Methods, 20S  
Recruitment of Participants in the Lung  
Health Study, II: Assessment of  
Recruiting Strategies, 38S

**MARKOV-LIKE SUSCEPTIBILITY  
MODEL**

- "Within Patient"-Dependent Outcomes  
in Graft Occlusion After Coronary  
Artery Bypass, 296

**METHODS**

- Design and Methods of a Clinical Trial  
for a Rare Condition: The  
Collaborative Ocular Melanoma  
Study, 362

**METHODS OR ISSUES**

- Operational and Policy Considerations of  
Data Monitoring in Clinical Trials:  
The Diabetes Control and  
Complications Trial Experience, 30

**MINIMAL DETECTABLE DIFFERENCE**

- Fixing the Number of Events in Large  
Comparative Trials With Low Event  
Rates: A Binomial Approach, 198

**MONITORING RULES**

- Statistical Design and Monitoring of the  
Carotene and Retinol Efficacy Trial  
(CARET), 308

**MULTICENTER CLINICAL TRIALS**

- In Defense of the Corporate Author for  
Multicenter Trials, 255  
Performance Evaluation in Multicenter  
Clinical Trials: Development of a  
Model by the AIDS Clinical Trial  
Group, 523

**NONCOMPLIANCE**

- Exclusion of "Noncompliant" Individuals  
from Clinical Trials (letter), 176

**NUISANCE PARAMETER**

- Stopping a Clinical Trial Very Early  
Because of Toxicity: Summarizing  
the Evidence, 286

**ODDS RATIO**

- Exact Repeated Confidence Intervals for  
Bernoulli Parameters in a Group  
Sequential Clinical Trial, 19

**OPTIC NEURITIS**

- Design, Methods, and Conduct of the  
Optic Neuritis Treatment Trial,  
123  
Quality Control Functions of the Visual  
Field Reading Center (VFRC) for the  
Optic Neuritis Treatment Trial  
(ONTT), 143

**ORGANIZATION**

- Operational and Policy Considerations of  
Data Monitoring in Clinical Trials:  
The Diabetes Control and  
Complications Trial Experience,  
30

**PARAMETRIC MODELS**

- Parametric Extrapolation of Survival  
Estimates with Applications to  
Quality of Life Evaluation of  
Treatments, 485

**PHARMACEUTICAL INDUSTRY**

- Interim Analysis in the Pharmaceutical  
Industry, 160

**PHYSICAL EXERCISE**

- The Oslo Diet and Exercise Study (ODES):  
Design and Objectives, 229

**PHYSICIAN REFERRAL**

- Recruitment Experience in the Full-Scale  
Phase of the Modification of Diet in  
Renal Disease Study, 538

**PLATINUM STANDARD**

- Tightening the Clinical Trial, 266

**POWER**

- Fixing the Number of Events in Large  
Comparative Trials With Low Event  
Rates: A Binomial Approach, 198

**PREGNANCY**

- The 1953 Clinical Trial of  
Diethylstilbestrol During  
Pregnancy: Could It Have Stopped  
DES Use?, 179



**PROTOCOL-SPECIFIED  
ADJUSTMENT**

Tightening the Clinical Trial, 266

**PULMONARY FUNCTION**

Design of the Lung Health Study: A  
Randomized Clinical Trial of Early  
Intervention for Chronic  
Obstructive Pulmonary Disease, 3S

**QUALITY CONTROL**

In Response to an Article by Lemuel Moyé  
(CCT 12(6)) Entitled "Central  
Laboratory Sampling Plans and  
Quality Control in Clinical Trials"  
(letters), 244, 247

Quality Control Functions of the Visual  
Field Reading Center (VFRC) for the  
Optic Neuritis Treatment Trial  
(ONTT), 143

**QUALITY-OF-LIFE**

Parametric Extrapolation of Survival  
Estimates with Applications to  
Quality of Life Evaluation of  
Treatments, 485

Perception of Quality of Life Before  
and After Disclosure of Trial  
Results: A Report from the Program  
on the Surgical Control of  
Hyperlipidemias (POSCH), 500

**QUANTITATIVE  
ARTERIOGRAPHY**

Design Features of a Controlled Clinical  
Trial to Assess the Effect of an HMG  
CoA Reductase Inhibitor on the  
Progression of Coronary Artery  
Disease, 45

**QUANTITATIVE  
ANGIOGRAPHY**

Effect of Cholesterol Reduction by  
Simvastatin on Progression of  
Coronary Atherosclerosis: Design,  
Baseline Characteristics, and  
Progress of the Multicenter Anti-  
Atheroma Study (MAAS), 209

**RADIO THERAPY**

Design and Methods of a Clinical Trial for  
a Rare Condition: The Collaborative  
Ocular Melanoma Study, 362

**RANDOMIZATION**

How Many Stratification Factors Are "Too  
Many" to Use in a Randomization  
Plan?, 98

The Use of Response-Adaptive Designs in  
Clinical Trials, 471

**RANDOMIZATION ANALYSIS**

Tightening the Clinical Trial, 266

**RANDOMIZED CLINICAL TRIAL**

A Method for the Analysis of Randomized  
Trials with Compliance  
Information: An Application to the  
Multiple Risk Factor Intervention  
Trial, 79

Recruitment Experience in the Full-Scale  
Phase of the Modification of Diet in  
Renal Disease Study, 538

**RANDOMIZED PLAY-THE-WINNER  
RULE**

The Use of Response-Adaptive Designs in  
Clinical Trials, 471

**RANDOMIZED TRIAL**

Design, Methods, and Conduct of the  
Optic Neuritis Treatment Trial, 123  
The Oslo Diet and Exercise Study (ODES):  
Design and Objectives, 229

**RARE CONDITION**

Design and Methods of a Clinical Trial for  
a Rare Condition: The Collaborative  
Ocular Melanoma Study, 362

**RECRUITMENT**

Monitoring Recruitment Effectiveness and  
Cost in a Clinical Trial, 52S

Recruiting Healthy Participants for a  
Large Clinical Trial, 68S

Recruitment Experience in the Full-Scale  
Phase of the Modification of Diet in  
Renal Disease Study, 538

Recruitment of Participants in the Lung  
Health Study, I: Description of  
Methods, 20S

Recruitment of Participants in the Lung  
Health Study, II: Assessment of  
Recruiting Strategies, 38S

**REGRESSION**

Design Features of a Controlled Clinical  
Trial to Assess the Effect of an HMG  
CoA Reductase Inhibitor on the  
Progression of Coronary Artery  
Disease, 45

**RELATIVE RISK**

Exact Repeated Confidence Intervals for  
Bernoulli Parameters in a Group  
Sequential Clinical Trial, 19



**REPEATED CONFIDENCE INTERVALS**

- Exact Repeated Confidence Intervals for Bernoulli Parameters in a Group Sequential Clinical Trial, 19
- Monitoring of Clinical Trials: Issues and Recommendations, 183

**SAMPLE SIZE**

- Fixing the Number of Events in Large Comparative Trials With Low Event Rates: A Binomial Approach, 198
- Research Cost Analyses to Aid in Decision Making in the Conduct of a Large Prevention Trial, CARET, 325
- Sample Size Requirements and Length of Study for Testing Interaction in a  $1 \times k$  Factorial Design when Time-to-Failure Is the Outcome, 511
- Statistical Design and Monitoring of the Carotene and Retinol Efficacy Trial (CARET), 308
- "Within Patient"-Dependent Outcomes in Graft Occlusion After Coronary Artery Bypass, 296

**SCREENING**

- Recruitment of Participants in the Lung Health Study, II: Assessment of Recruiting Strategies, 38S

**SEQUENTIAL ANALYSIS**

- Stopping a Clinical Trial Very Early Because of Toxicity: Summarizing the Evidence, 286

**SIMVASTATIN**

- Effect of Cholesterol Reduction by Simvastatin on Progression of Coronary Atherosclerosis: Design, Baseline Characteristics, and Progress of the Multicenter Anti-Atheroma Study (MAAS), 209

**SMOKING CESSATION**

- A Method for the Analysis of Randomized Trials with Compliance Information: An Application to the Multiple Risk Factor Intervention Trial, 79

**STATIC PERIMETRY**

- Quality Control Functions of the Visual Field Reading Center (VFRC) for the Optic Neuritis Treatment Trial (ONTT), 143

**STOCHASTIC CURTAILMENT**

- Monitoring of Clinical Trials: Issues and Recommendations, 183
- Statistical Considerations in Monitoring the Systolic Hypertension in the Elderly Program (SHEP), 350

**STRATIFICATION**

- How Many Stratification Factors Are "Too Many" to Use in a Randomization Plan?, 98

**SURFACANT TRIALS**

- Treatment Effect Size in Clinical Trials: An Example from Surfactant Trials, 467

**SURVIVAL ANALYSIS**

- Parametric Extrapolation of Survival Estimates with Applications to Quality of Life Evaluation of Treatments, 485

**SURVIVAL CURVES**

- A Computer Program for Designing Clinical Trials with Arbitrary Survival Curves and Group Sequential Testing, 109

**SUSPENDED JUDGMENT**

- The 1953 Clinical Trial of Diethylstilbestrol During Pregnancy: Could it Have Stopped DES Use?, 179
- Concerning Silverman's Suspended Judgment Article "The Most Noble Goal Of Medicine" Published December 1991 (letter), 174
- Instituting a Research Ethic, 261
- $n$ -of-1 Trials, 1
- Simple Explanations for Complex Systems: Surprising and Unexpected Outcomes, 75
- From "Tame" to "Forbidden" death, 347
- Treatment Effect Size in Clinical Trials: An Example from Surfactant Trials, 467

**TIME DEPENDENT COVARIATE**

- A Method for the Analysis of Randomized Trials with Compliance Information: An Application to the Multiple Risk Factor Intervention Trial, 79

**TIME-TO-FAILURE**

- Sample Size Requirements and Length of Study for Testing Interaction in a  $1 \times k$  Factorial Design when Time-to-Failure Is the Outcome, 511

**TREATMENT ALLOCATION**

The Use of Response-Adaptive Designs in Clinical Trials, 471

**TREATMENT EFFECT SIZE**

Treatment Effect Size in Clinical Trials:  
An Example from Surfactant Trials, 467

**TREATMENT EFFECTS MONITORING**

Operational and Policy Considerations of Data Monitoring in Clinical Trials: The Diabetes Control and Complications Trial Experience, 30

**TREATMENT IMBALANCE**

How Many Stratification Factors Are "Too Many" to Use in a Randomization Plan?, 98

**VISUAL FIELDS**

Quality Control Functions of the Visual Field Reading Center (VFRC) for the Optic Neuritis Treatment Trial (ONTT), 143

**ZIDOVUDINE**

Ethical Dilemmas in Continuing a Zidovudine Trial After Early Termination of Similar Trials, 6